Preservation solutions used during abdominal transplantation: Current status and outcomes

Table 2 Selected clinical studies involving liver preservation solutions

Ref.	Solution	Cases	Patient survival	Graft survival
UW vs HTK
Erhard et al[43]	UW vs HTK	60 (UW 30, HTK 30)	No diff (30 mo)	No diff (3 mo)
			(UW 74%, HTK 77%)	(UW 80%, HTK 87%)
Mangus et al[44]	UW vs HTK	378 (UW 204, HTK 174)	No diff (1 yr)	No diff (1 yr)
			(UW 84.6%, HTK 82.1%)	(UW 81.7%, HTK 80.8%)
Rayya et al[45]	UW vs HTK	137 (UW 68, HTK 69)	No diff (1 yr)	No diff (1 yr)
			(UW 78%, HTK 78%)	(UW 78%, HTK 71%)
Mangus et al[51]	UW vs HTK	698 (UW 327, HTK 371)	No diff (1 yr)	No diff (1 yr)
			(UW 88%, HTK 87%)	(UW 84%, HTK 86%)
Avolio et al[46]	UW vs HTK	39 (UW 22, HTK 17)	No diff (not stated)	No diff (6 mo)
			(UW 82%, HTK 88%)	(UW 80.9%, HTK 85.7%)
Canelo et al[47]	UW vs HTK	134 (UW 71, HTK 63)	No diff	No diff
Celsior vs (HTK or UW)
Nardo et al[57]	CEL vs HTK	40 (CEL 20, HTK 20)	No diff (1 yr)	No diff (1 yr)
			(CEL 90%, HTK 85%)	(CEL 90%, HTK 75%)
García-Gil et al[56]	CEL vs UW	80 (CEL 40, UW 40)	No diff (1 yr)	No diff (1 yr)
			(CEL 85.7%, UW 79.8%)	(CEL 78%, UW 75.5%)
Cavallari et al[55]	CEL vs UW	173 (CEL 83, UW 90)	No diff (1 yr)	No diff (1 yr)
			(CEL 87%, UW 89%)	(CEL 85%, UW 83%)
Lopez-Andujar et al[53]	CEL vs UW	196 (CEL 92, UW 104)	No diff (1 yr)	No diff (1 yr)
			(CEL 83%, UW 83%)	(CEL 81%, UW 80%)
Pedotti et al[54]	CEL vs UW	175 (CEL 79, UW 96)	No diff (1 yr)	No diff (1 yr)
			(CEL 89.9%, UW 90.6%)	(CEL 83.3%, UW 85.4%)

Diff: Difference; UW: University of Wisconsin; CEL: Celsior; HTK: Histidine-tryptophan-ketoglutarate.